The ATP-binding cassette transporters ABCB1 and ABCC1 are not regulated by hypoxia in immortalised human brain microvascular endothelial cells
© Patak et al; licensee BioMed Central Ltd. 2011
Received: 16 October 2011
Accepted: 26 October 2011
Published: 26 October 2011
ATP-binding cassette transporters at the blood-brain barrier are actively regulated upon ischemic stroke in a way that impedes the access of pharmacological compounds to the brain tissue. The luminal endothelial transporter ABCB1 was recently shown to be increased, whereas the abluminal transporter ABCC1 was decreased on ischemic brain capillaries. In vitro studies using epithelial cells suggested that ABCB1 is regulated during hypoxia in a hypoxia-inducible factor (HIF)-1α-dependent way.
In order to investigate whether hypoxia might be responsible for the expression changes of ABCB1 and ABCC1 in the ischemic brain, the immortalised human brain microvascular endothelial cell line hCMEC/D3 was exposed to hypoxia (1%) or anoxia (0%). Cell lysates were analysed by Western blot to detect the protein expression of ABCB1, ABCC1, HIF-1α and HIF-2α.
During hypoxia, an accumulation of HIF-1α and HIF-2α was noticed in hCMEC/D3 cells that followed different time kinetics. Both HIF-1α and HIF-2α abundance increased within 4 h of hypoxia. HIF-1α levels decreased to below detection levels within 16 h of hypoxia, whereas HIF-2α remained elevated even after 48 h. No changes of ABCB1 and ABCC1 expression were detected, neither on the mRNA nor protein level.
Our data suggests that other factors than hypoxia may be responsible for the expression changes of ATP-binding cassette transporters in the ischemic brain.
KeywordsBlood-brain barrier hypoxia-inducible factor multidrug resistance stroke
ATP-binding cassette (ABC) transporters are efflux proteins that are abundantly expressed at the blood-brain barrier [1, 2]. ABC transporters protect the brain from toxic compounds, but at the same time they prevent the access of drugs into the brain [1, 2]. In brain disease, changes of ABC transporter expression and hence function have been demonstrated to modulate barrier properties . Upon ischemia, ABC transporters are regulated on brain capillary endothelial cells in a coordinated way that impedes the delivery of drugs into the brain. As such, the luminal transporter ABCB1, which transfers its substrates from the brain into the blood, was increased , whereas the abluminal transporter ABCC1, which carries its substrates in the opposite direction, i.e. from blood to brain was decreased  following middle cerebral artery occlusion (MCAO) in mice. The altered abundance had a major impact on the biodistribution of drugs in the brain and resulted in a poorer delivery of neuroprotective drugs to the post-ischaemic brain, despite a stroke-related impairment of blood-brain barrier integrity [3, 4].
Understanding the regulatory mechanisms of the luminal to abluminal ABC transporter balance is an important challenge for brain pharmacology, as it may identify strategies that improve the access of drugs to the brain. Interestingly, the expression of ABCB1 has previously been shown to be regulated in hypoxic epithelial cells in a hypoxia-inducible factor (HIF)-1α-dependent way . Since hypoxia is a major factor contributing to ischemic injury, we were intrigued by the question whether HIF-1α-dependent signaling is also responsible for the ischemia-induced expression changes of ABC transporters in endothelial cells. To elucidate this issue, we exposed the cells of the immortalised human brain microvascular endothelial cell line hCMEC/D3 to conditions of ambient hypoxia.
hCMEC/D3 cells were propagated in Microvascular Endothelial Cell Medium-2 (EGM-2MV; obtained from Lonza, Allendale, NJ, U.S.A.) . Cells from passage 25 to 35 were grown on surfaces coated with 100 μg/ml rat tail collagen type-I (BD Biosciences, Heidelberg, Germany). Cells were plated on collagen-coated 60 mm dishes and placed in a hypoxia chamber (oxygen concentration: 1%). In additional studies, HIF-1α was chemically induced by supplementing the cells with the iron chelator deferoxamine mesylate (DFO) (0.1 mM; Sigma-Aldrich, Deisenhofen, Germany) or the prolyl-4 hydroxylase inhibitor dimethyloxaloyl glycine (DMOG) (1 mM; Alexis Biochemicals, Lörrach, Germany). To generate oxygen concentrations close to anoxia, cells were furthermore incubated in GasPak (BBL) anoxic jars using BD GasPak EZ anoxic container systems (BD Diagnostic Systems, Heidelberg, Germany). The duration of hypoxia or anoxia exposure is specified below. All experiments were performed at least three times.
The monoclonal antibody against human HIF-1α (610959) was purchased from BD Biosciences (Heidelberg, Germany). The polyclonal antibody against HIF-2α (AF 2886) was from R&D Systems (Wiesbaden-Nordenstadt, Germany). The polyclonal antibody against ABCB1 (sc-8313) was from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.) and the monoclonal antibody against ABCC1 was purchased from Alexis Biochemicals (Lörrach, Germany). The polyclonal antibody against actin (A2103) was from Sigma-Aldrich. The goat polyclonal, horse radish peroxidase (HRP)-conjugated antibodies raised against rabbit (PO448) and mouse (PO447) IgG were purchased from DAKO (Hamburg, Germany).
Western blotting for ABCB1 and ABCC1 was performed as described previously . Briefly, cell lysates were prepared using RIPA lysis buffer (50 mM Tris pH 7.5, 0.1% SDS, 1% Nonidet P40, 0.5% sodium deoxycholate, 2 mM EDTA, 150 mM NaCl) containing protease inhibitor cocktail (Roche, Mannheim, Germany). Protein samples were separated on 7.5% reducing SDS gels and blotted onto PVDF membranes. After the transfer, blocking of unspecific binding sites was achieved by incubation in Tris-buffered saline (50 mM Tris/HCl, 150 mM NaCl) containing 0.5% Tween 20 (TBST, pH 7.2) and 5% skimmed milk. Washed membranes were incubated overnight at 4°C with antibody against ABCB1 (1:1000 in TBST) or ABCC1 (1:200 in TBST) and for 2 h at 20°C with antibody against HIF-1α (1:1000 in TBST) and HIF-2α (1:1000 in TBST). Following incubation with HRP-conjugated secondary antibodies, the target proteins were detected with the enhanced chemoluminescence (ECL) kit (GE Healthcare, Munich, Germany) using an FX7 chemoluminescence documentation system (Peqlab, Erlangen, Germany).
Real time quantitative PCR (rt-PCR)
Total RNA was extracted from hCMEC/D3 cells with RNeasy Midi Kit (Qiagen, Hilden, Germany) according to manufacturer's protocol. 1 μg RNA was reverse-transcribed to cDNA. The following abcb1 and abcc1 primers were used: abcb1 (84 bp): 5', AAA TTG GCT TGA CAA GTT GTA TAT GG; 3', CAC CAG CAT CAT GAG AGG AAG TC; abcc1 (139 bp): 5', TCT ACC TCC TGT GGC TGA ATC TG; 3', CCG ATT GTC TTT GCT CTT CAT G. In our studies, succinate dehydrogenase (sdha) was analysed as housekeeping gene using primers provided by Qiagen (cat.-no.: QT00059486). Abcb1, abcc1 and sdha mRNA expression was analysed using SYBR® green as fluorescent dye (Eurogentec, Verviers, Belgium) on the Step One Plus Real Time PCR Detection System (Applied Biosystems, Darmstadt, Germany) in a two-step rt-PCR. The denaturation steps were performed at 95°C for 10 min followed by 40 cycles at 95°C for 15 s, and at 60°C for 1 min. Rt-PCR was always performed in duplicates, for which mean values were determined. Amounts of cDNA were normalized to sdha using the Δct method, as previously described .
HIF-1α and HIF-2α expression in hCMEC/D3 cell line during normoxia and hypoxia
Kinetics of HIF-1α and HIF-2α expression in hCMEC/D3 during hypoxia
ABCB1 and ABCC1 expression remains unchanged in hCMEC/D3 cells during hypoxia and anoxia
We report that ABC transporters are not regulated by hypoxia in the immortalised human brain microvascular endothelial cell line hCMEC/D3, which provides a unique and accessible in vitro system to study protein responses during sustained oxygen deprivation . Our interest was sparked by in vivo studies in a model of MCAO that demonstrated an increase of ABCB1  and a decrease of ABCC1  protein levels on the surface of ischemic cerebral microvessels. Studies in the epithelial cell lines OKF6, T84 and Caco-2 had shown that the ABCB1 transporter was regulated in a HIF-1α-dependent way upon hypoxia . Thus, we hypothesized that ABCB1 expression in human brain microvascular endothelial cells may also be enhanced as a consequence of HIF activation.
In our study, both HIF-1α and HIF-2α were found to be induced upon hypoxia. While HIF-2α exhibited a long-lasting accumulation in the brain endothelial cell line, HIF-1α levels were only transiently increased. While HIF-1α is known to be expressed in virtually all tissues, HIF-2α has been shown to be restricted to certain cell types including endothelial cells, cells of the kidney, liver, lungs and pancreas . However, no changes in ABCB1 or ABCC1 protein levels were detected in our present study, despite a strong induction of HIF-1α and HIF-2α in the hCMEC/D3 cells, suggesting that HIF might not be essential for ABC transporter regulation in cerebral microvessels. The regulation of both transporters seen in cerebral ischaemia could depend on other factors than hypoxia alone that go hand in hand with ischaemia and have been described to induce ABCB1 expression, such as glucose depletion  or reactive oxygen species that are generated by reoxygenation as shown in rat brain endothelial cells [10, 11].
To our knowledge only three other studies have so far examined the effect of hypoxia on ABC transporters in brain endothelial cells. In a primary rat brain endothelial cell model of hypoxia/reoxygenation, either induced by hydrogen peroxide administration or by reoxygenation following 6 hours of sustained hypoxia, Felix and Barrand  showed increased levels of ABCB1 6 hours following hypoxia and then again 24 hours following reoxygenation. Robertson et al.  studied the expression of ABCB1 in primary and immortalised rat brain endothelial cells that underwent hypoxia/reoxygenation. Exposure of primary rat brain endothelial cells to 6 hours of hypoxia alone revealed no changes in ABCB1 protein levels compared to normoxic controls. Significant increases in ABCB1 levels were only observed 24 h after 6 h hypoxia with reoxygenation. Xiao-Dong et al.  observed that repetitive hypoxia/reoxygenation may induce an up-regulation of ABCB1 in cultured rat brain microvascular endothelial cells. In that study, cells underwent hypoxia by covering the cells with paraffin oil once daily for 15 min over a time period of 8 days. None of the authors so far investigated the effect of over-night exposure to hypoxia on ABCB1 levels.
We did not investigate reoxygenation conditions in the present study, since we were interested in the role of HIF-1α and HIF-2α in the regulation of ABC transporters. Neither did we investigate ABC transporter expression in co-culture with human astrocytes that are known to have a regulatory function at the blood-brain barrier . Based on the data presented here, it seems that the responses of ABC transporters to hypoxia are less distinct than previously presumed. This is underlined by recent observations in prostate carcinoma cells, showing that the protein expression of ABCB1 and ABCC1 were independent of tissue oxygen levels . Our results support the idea that the mechanisms controlling the expression of ABCB1 and ABCC1 are cell specific. Thus, hypoxia does not seem to play a major role in the regulation of ABC transporters in cerebral microvessels.
This is the first study examining the expression of HIF and ABC transporters under sustained hypoxia in a human cell model of the blood-brain barrier. Despite a strong induction of HIF-1α and HIF-2α, this study did not detect a regulation of the transporters ABCB1 and ABCC1, indicating that neurovascular signals other than HIF-1α and HIF-2α are responsible for the expression changes of ABC transporters after MCAO.
We thank Dr. Pierre-Olivier Couraud (Institut Cochin, INSERM, Paris) for providing hCMEC/D3 cells. Supported by the German Research Foundation (HE3173/2-1 and HE3173/3-1, to D.M.H.) and Heinz-Nixdorf Foundation.
- Löscher W, Potschka H: Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005, 2: 86–98. 10.1602/neurorx.2.1.86PubMed CentralPubMedView ArticleGoogle Scholar
- Hermann DM, Kilic E, Spudich A, Krämer SD, Wunderli-Allenspach H, Bassetti CL: Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 2006, 60: 489–498. 10.1002/ana.21012PubMedView ArticleGoogle Scholar
- Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, Hermann DM: Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischaemia. Nat Neurosci 2006, 9: 487–8. 10.1038/nn1676PubMedView ArticleGoogle Scholar
- Kilic E, Spudich A, Kilic U, Rentsch KM, Vig R, Matter CM, Wunderli-Allenspach H, Fritschy JM, Bassetti CL, Hermann DM: ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain 2008, 131: 2679–89. 10.1093/brain/awn222PubMedView ArticleGoogle Scholar
- Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002, 62: 3387–94.PubMedGoogle Scholar
- Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO: Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005, 19: 1872–4.PubMedGoogle Scholar
- ElAli A, Hermann DM: Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. Sci Signal 2010, 3: ra72. 10.1126/scisignal.2001213PubMedGoogle Scholar
- Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC: Differential roles of hypoxia-inducible factor 1-alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003, 23: 9361–74. 10.1128/MCB.23.24.9361-9374.2003PubMed CentralPubMedView ArticleGoogle Scholar
- Ledoux S, Yang R, Friedlander G, Laouari D: Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 2003, 63: 7284–90.PubMedGoogle Scholar
- Felix RA, Barrand MA: P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem 2002, 80: 64–72. 10.1046/j.0022-3042.2001.00660.xPubMedView ArticleGoogle Scholar
- Robertson SJ, Kania KD, Hladky SB, Barrand MA: P-glycoprotein expression in immortalised rat brain endothelial cells: comparisons following exogenously applied hydrogen peroxide and after hypoxia-reoxygenation. J Neurochem 2009, 111: 132–41. 10.1111/j.1471-4159.2009.06306.xPubMedView ArticleGoogle Scholar
- Xiao-Dong L, Zhi-Hong Y, Hui-Wen Y: Repetitive/temporal hypoxia increased P-glycoprotein expression in cultured rat brain microvascular endothelial cells in vitro. Neurosci Lett 2008, 432: 184–7. 10.1016/j.neulet.2007.12.017PubMedView ArticleGoogle Scholar
- Abbott NJ, Rönnbäck L, Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7: 41–53. 10.1038/nrn1824PubMedView ArticleGoogle Scholar
- Thews O, Gassner B, Kelleher DK, Gekle M: Activity of drug efflux transporters in tumor cells under hypoxic conditions. Adv Exp Med Biol 2008, 614: 157–64. 10.1007/978-0-387-74911-2_19PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.